|
|
Article: FDA approves InSync Maximo cardiac resynchronization therapy defibrillator.
- Article from:
- Medical Devices & Surgical Technology Week
- Article date:
- August 1, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 AUG 1 - (NewsRx.com & NewsRx.net) -- Medtronic, Inc., (MDT) announced U.S. Food and Drug Administration approval and commercial release of the InSync Maximo cardiac resynchronization therapy (CRT) defibrillator system.
The InSync Maximo device incorporates proven cardiac resynchronization therapy to treat heart failure and the capacity to deliver high-output defibrillation energy to stop a lethally fast heart rhythm.
With 35 joules of delivered energy and the industry's fastest charge times, InSync Maximo provides the highest margin of safety in treating sudden cardiac arrest.
Charge time is the number of seconds between the time the ...